Page last updated: 2024-11-07

aldosterone and Cardiomyopathy, Hypertrophic

aldosterone has been researched along with Cardiomyopathy, Hypertrophic in 9 studies

Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19901 (11.11)18.7374
1990's1 (11.11)18.2507
2000's3 (33.33)29.6817
2010's3 (33.33)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Mendes, LC1
de Oliveira Magalhães, R1
Pereira Dos Santos, RK1
Araújo, RS1
Ramchand, J1
Sampaio Rodrigues, T1
Yudi, MB1
Burrell, LM1
Orenes-Piñero, E1
Hernández-Romero, D1
Romero-Aniorte, AI1
Martínez, M1
García-Honrubia, A1
Caballero, L1
Garrigos-Gómez, N1
Andreu-Cayuelas, JM1
González, J1
Feliu, E1
Climent, V1
Nicolás-Ruiz, F1
De La Morena, G1
Valdés, M1
Lip, GY1
Marín, F1
Tarjus, A1
Martínez-Martínez, E1
Amador, C1
Latouche, C1
El Moghrabi, S1
Berger, T1
Mak, TW1
Fay, R1
Farman, N1
Rossignol, P1
Zannad, F1
López-Andrés, N1
Jaisser, F1
Tsybouleva, N1
Zhang, L1
Chen, S1
Patel, R1
Lutucuta, S1
Nemoto, S1
DeFreitas, G1
Entman, M1
Carabello, BA1
Roberts, R1
Marian, AJ1
de Resende, MM1
Kriegel, AJ1
Greene, AS1
Chai, W1
Hoedemaekers, Y1
van Schaik, RH1
van Fessem, M1
Garrelds, IM1
Saris, JJ1
Dooijes, D1
ten Cate, FJ1
Kofflard, MM1
Danser, AH1
Brilla, CG1
Rupp, H1
Funck, R1
Maisch, B1
Kohyama, J1
Watanabe, S1
Fukuda, C1
Shimozawa, K1
Saitoh, K1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998]Phase 4260 participants (Anticipated)Interventional2018-05-14Not yet recruiting
Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060]Phase 453 participants (Actual)Interventional2007-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo.

Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

,
Interventionmicrograms/L (Mean)
Baseline (PINP)12 Months (PINP)Baseline (PIIINP)12 Months (PIIINP)Baseline (ICTP)12 Months (ICTP)
Placebo Control2.10.64.51.62.5-2.3
Spironolactone2.10.74.72.02.22.7

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Left Atrial Dimension (in mm)

CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)

,
Interventionmillimeters (Mean)
Left Atrial Dimension (Baseline)Left Atrial Dimension (12-Month Follow-Up)
Placebo Control4140
Spironolactone4040

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Left Ventricular End-Diastolic (LVED) Cavity Size (in mm/m^2)

CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)

,
Interventionmm/m^2 (Mean)
LVED Cavity Size (Baseline)LVED Cavity Size (12-Month Follow-Up)
Placebo Control145146
Spironolactone133129

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Maximum Left Ventricular Wall Thickness (in mm)

CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

,
Interventionmillimeters (Mean)
Maximum Left Ventricular Wall Thickness (Baseline)Maximum Left Ventricular Wall Thickness (12-Month Follow-Up)
Placebo Control2119
Spironolactone2222

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Percentage of Left Ventricular Mass (%LV)

CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

,
InterventionPercentage of Total LV Mass (Mean)
LGE Assessment of Myocardial Fibrosis (Baseline)LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up)
Placebo Control2.52.8
Spironolactone1.11.8

Measure of Functional Capacity: Peak Oxygen Consumption With Exercise

This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

,
Interventionml/kg/min (Mean)
Peak VO2 (Baseline)Peak VO2 (12-Month Follow-Up)
Placebo Control2829
Spironolactone3029

Measure of Heart Failure Symptoms According to the New York Heart Association Functional Class

This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)

,
Interventionscore on a scale (Mean)
NYHA Class (Baseline)NYHA Class (12-Month Follow Up)
Placebo Control1.51.6
Spironolactone1.61.7

Measure of Indices of Diastolic Function by Tissue Doppler Echocardiography (Septal E/e')

This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

,
InterventionRatio (Mean)
Diastolic Function (Baseline)Diastolic Function (12-month Follow-Up)
Placebo Control1513
Spironolactone1413

Reviews

1 review available for aldosterone and Cardiomyopathy, Hypertrophic

ArticleYear
The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure.
    European heart journal, 1995, Volume: 16 Suppl O

    Topics: Adult; Aldosterone; Cardiomyopathy, Hypertrophic; Cell Division; Collagen; Connective Tissue; Corona

1995

Other Studies

8 other studies available for aldosterone and Cardiomyopathy, Hypertrophic

ArticleYear
Pseudohypoaldosteronism associated with hypertrophic cardiomyopathy, hypertension and thrombocytosis due to mutation in the ELAC2 gene: a case report.
    Journal of pediatric endocrinology & metabolism : JPEM, 2022, Nov-25, Volume: 35, Issue:11

    Topics: Aldosterone; Cardiomyopathy, Hypertrophic; Child; Humans; Hypertension; Mutation; Neoplasm Proteins;

2022
Further studies needed before using renin-angiotensin-aldosterone system blockade for atrial fibrillation prevention in hypertrophic cardiomyopathy.
    Heart (British Cardiac Society), 2018, Volume: 104, Issue:23

    Topics: Aldosterone; Angiotensins; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Humans; Renin; Renin-A

2018
Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy.
    QJM : monthly journal of the Association of Physicians, 2014, Volume: 107, Issue:8

    Topics: Adult; Aged; Aldosterone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Case-Control Studies; C

2014
Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids.
    Hypertension (Dallas, Tex. : 1979), 2015, Volume: 66, Issue:1

    Topics: Acute-Phase Proteins; Aldosterone; Animals; Aorta; Cardiomyopathy, Hypertrophic; Cells, Cultured; Cy

2015
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells

2004
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells

2004
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells

2004
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells

2004
Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy.
    Journal of cardiovascular pharmacology, 2006, Volume: 48, Issue:6

    Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals

2006
Cardiac aldosterone in subjects with hypertrophic cardiomyopathy.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2006, Volume: 7, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Cardiomyopathy, Hypertrophic; Cytochrome P-

2006
Adrenocorticotropic hormone unresponsiveness associated with hypertrophic cardiomyopathy.
    Acta paediatrica Scandinavica, 1989, Volume: 78, Issue:3

    Topics: 17-Ketosteroids; Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Cardiomyopathy, Hypertrop

1989